Peter Louwagie

SVP Corporate Development at Genmab

Speaker

Peter has more than twenty years of experience in inbound and outbound transactions in the biopharma sector. He has acquired a deep understanding of the transaction environment in our industry. He is currently Senior Vice President Corporate & Business Development at Genmab, responsible for all the transactions that encompass discovery, clinical and commercial stage. Under his leadership, Genmab transacted its first M&A in its history in 2024 by acquiring ProfoundBio for $1.8B, followed by the acquisition of Merus NV for $8.0B in 2025 being Genmab’s first public M&. Prior to joining Genmab, Peter worked for more than a decade at Novartis in Basel, Switzerland as Head Transactions Immunology, Global Head BD&L Neuroscience and Deputy Head Global M&A executing multiple transactions such as Novartis first RLT and gene-therapy acquisitions as well as the spinouts of Alcon and Sandoz. He started his career in the biopharma sector in the M&A department of UCB SA in Brussels, Belgium.

He began his career at PwC (former Coopers & Lybrand) as Certified Public Auditor and Tax Consultant. Peter holds an engineering degree in Applied Economics with majors in Accountancy and Tax from the Catholic University of Leuven, Belgium.